COMMUNIQUÉS West-GlobeNewswire

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
05/02/2026
CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026
04/02/2026
Daix (France), New York ( États-Unis ), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales [...]
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
04/02/2026
SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
MEN Balance Pro Consumer Report (2026): Public Product Information and Evaluation Factors (Not a Review)
04/02/2026
An informational overview examining MEN Balance Pro refund policy terms, retailer disclosures, ingredient transparency, and what consumers evaluate when researching men's wellness supplement options in 2026 WILMINGTON, [...]
Max Force Power Male Enhancement Gummies Product Information Updated as Consumer Interest in Male Vitality Supplement Options Grows in 2026
05/02/2026
An informational overview examining male enhancement supplement category trends, publicly available ingredient disclosures, consumer evaluation criteria, and what adults researching male vitality supplement options [...]
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other [...]
Monthly information on share capital and company voting rights
04/02/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Olema Oncology to Participate in Upcoming Investor Conferences
04/02/2026
SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
ChemoMetec enters Letter of Intent with Roche Diagnostics
04/02/2026
ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating [...]
Interim report 2025/26 - Organic growth despite challenges in the North American market
04/02/2026
ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was [...]
New NMDP-Sponsored Trial Data Show Comparable Patient-Reported Outcomes and Survival Across Levels of Genetic Mismatch
04/02/2026
ACCESS trial results at the 2026 Tandem Meetings reinforce mismatched unrelated donors as safe, effective and well-tolerated option Practice-advancing research conducted through CIBMTR demonstrates collaborative, [...]
CROSSJECT - NOVEMBRE 2026 : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT
04/02/2026
Communiqué de Presse Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT Dijon, le 04 février 2026 Au titre du contrat de liquidité confié par la société CROSSJECT à Rothschild [...]
Glow Holdings, Inc. Provides Corporate Update Following GlohCo Introduction and Initial Industry Engagement
04/02/2026
HOUSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Glow Holdings, Inc. (OTC: GLOH), doing business as GlohCo, today provided a corporate update following the recent introduction of its GlohCo health intelligence platform and [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ la société pharmaceutique de [...]
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
04/02/2026
Agreement expands offering to include additional sheet, particulate and flowable products MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it [...]
Lightship Inc. Acquires Veda Trials to Expand Community-Based Clinical Research Delivery
04/02/2026
The acquisition expands scalable trial operations across real-world care settings RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Lightship Inc. , the modern clinical trial site organization committed to [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
SAFE - Croissance de 6,5 % du chiffre d’affaires 2025 - Confirmation de la feuille de route
04/02/2026
Croissance de 6,5 % du chiffre d’affaires 2025 Confirmation de la feuille de route Fleurieux-sur-l’Arbresle - France - le 4 février 2026 à 18h. Safe Group publie son chiffre d’affaires annuel consolidé pour l'exercice [...]

Pages